Search Results

You are looking at 1 - 10 of 221 items for :

  • Haematology, Oncology x
Clear All
Open access

Nikolaos Soupos, Konstantinos Laschos, Evangelos Bournakis, Euthymios Kostouros and Gerasimos Aravantinos

combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep;49(14):2972-8. doi: 10.1016/j. ejca.2013.05.020. Epub 2013 Jun 27. [18] Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011 May 1;121(2):353-7. doi: 10.1016/j.ygyno.2011.01.020. Epub 2011 Feb 15. [19] Camille C Gunderson , Kathleen N

Open access

Amrallah A. Mohammed

FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev 2001, Issue 4. Art No: CD001316. DOI: 10.1002/14651858.CD001316. [17] Bruera E, Ripamonti C. Dyspnea in patients with advanced cancer. In: Berger A, Portenoy R, Weissman D, editors. Principles and practice of supportive oncology. Philadelphia: Lippincott-Raven; 1998. 295–308. [18] Pereira J, Mancini I, Bruera E. The management of bleeding in patients with advanced cancer. In: Portenoy RK, Bruera E, eds. Topics in

Open access

Anastasios Kyriazoglou, Ioannis Dimitriadis and Aristotelis Bamias

Renal Cell C the Japanese Urological A. Evidence-based clinical practice guideline for renal cell carcinoma: the Japanese Urological Association 2011 update Int J Urol 2012 Jun 19 6 496 503 [4] Bazarbashi S, Alkhateeb S, Abusamra A, Rabah D, Alotaibi M, Almansour M, et al. Saudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinoma. Urol Ann2014 Oct;6(4):286-9. 10.4103/0974-7796.140974 Bazarbashi S Alkhateeb S Abusamra A Rabah D Alotaibi M Almansour M Saudi oncology society and Saudi urology

Open access

Abeer Hussien Anter

-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55:594-605. [6] Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007; 25(11):1423-1436. [7] McQuay HJ, Collins SL, Carroll D, Moore RA. Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev. 2000;(2):CD001793. [8] Chow E, Danjoux C, Wong R, et al. Palliation of bone metastases: a survey of patterns of practice among

Open access

Panagiota Economopoulou and Amanda Psyrri

2013 Oct 1 19 19 5542 [7] Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23. 10.1056/NEJMoa1003466 Hodi FS O’Day SJ McDermott DF Weber RW Sosman JA Haanen JB et al Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 2010 Aug 19 363 8 711 23 [8] Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med

Open access

Alexios Matikas and Sofia Aggelaki

revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694-705. 10.1097/JTO.0b013e31812d05d5 Groome PA Bolejack V Crowley JJ Kennedy C Krasnik M Sobin LH et al The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours J Thorac Oncol 2007 2 8 694 705 [3] Rosell R, Carcereny E

Open access

Rasha Hamdy Hamed, Khalid Salim, Abdullah Alzahrani and Shereef Elsamany

dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215. 10.1200/JCO.2002.20.5.1215 Seidman A Hudis C Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 2002 20 1215 [17] Wysocki PJ, Hutka M: Cardiotoxicity of 5-fluorouracil in a young colorectal cancer patient - case report and review of literature. Arch Med Sci 2009, 5:277-280. Wysocki PJ Hutka M Cardiotoxicity of 5-fluorouracil in a young colorectal cancer patient - case report and review of literature Arch Med Sci 2009 5 277 280 [18

Open access

Mokhtar M Galila, Ebeid FS Fatma, Ishak AI Sherif, Ragab A Iman and Yousef AS Khaled

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 23 9 2004 2011 [10] Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, Marina N, Leavey P, Gebhardt M, Healey J et al: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. Journal of clinical oncology : official

Open access

E. Veniou, I. Sofatzis, I. Kalantzis, M. Karakosta, M. Logothetis, E. Lianos and N. Ziras

2009; 120:1640-1645. Alberti KG Eckel RH Grundy SM Zimmet PZ Cleeman JI Donato KA Fruchart JC James WP Loria CM Smith SC Jr Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 2009 120 1640 1645 [2] Haslam DW, James WP. Obesity. Lancet 2005; 366:1197-1209. 10.1016/S0140-6736(05

Open access

K. 1 , Metaxa-Mariatou V. 1 , Stamou E. 1 , Aravadinos G. 2 , Varthalitis I. 3 , Kambletsas E. 4 , Kesisis G. 5 , Boukovinas I. 6 , Papakotoulas P. 7 , Katirtzoglou N. 8 , Athanasiadis I 9 , Stavridi F. 10 , Christodoulou C. 11 , Koumarianou A. 12 , Nasioulas G. 1 1. GENEKOR MSA 2. SECOND DEPARTMENT OF MEDICAL ONCOLOGY, AGII ANARGIRI CANCER HOSPITAL, ATHENS 3. 1ST ONCOLOGY DEPARTMENT HENRY DUNANT HOSPITAL CENTER 4. DEPARTMENT OF MEDICAL ONCOLOGY, IOANNINA UNIVERSITY HOSPITAL 5. ONCOLOGY DEPARTMENT, ``SAINT LUKE`` PRIVATE HOSPITAL 6. BIOCLINIC